Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autism Spectrum Disorder01:19

Autism Spectrum Disorder

506
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
506
Modeling in Therapy01:26

Modeling in Therapy

208
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
208
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

295
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
295
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

481
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.

Schizophrenia (Heidelberg, Germany)·2025
Same author

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.

Schizophrenia (Heidelberg, Germany)·2025
Same author

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.

Schizophrenia (Heidelberg, Germany)·2025
Same author

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2025
Same author

Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factors.

Psychological medicine·2025
Same author

Prioritizing Brain Health in Youth: Bringing Neuroscience to Society and Informing Policy, Lessons Learnt from the European Brain Council Expert Meeting Held at the Federation of European Neuroscience Societies Forum 2024.

The European journal of neuroscience·2025

Related Experiment Video

Updated: Nov 1, 2025

Author Spotlight: Exploring Autism Spectrum Disorder Symptoms in Fruit Flies — Genetic Models and Behavioral Tests
08:30

Author Spotlight: Exploring Autism Spectrum Disorder Symptoms in Fruit Flies — Genetic Models and Behavioral Tests

Published on: September 6, 2024

2.1K

Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions.

James T McCracken1, Evdokia Anagnostou2, Celso Arango3

  • 1Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|June 23, 2021
PubMed
Summary
This summary is machine-generated.

Autism Spectrum Disorder (ASD) research faces challenges like heterogeneity and lack of biomarkers. New strategies leveraging genetics and digital phenotyping offer optimism for developing effective ASD therapeutics.

Keywords:
AutismBiomarkersChildrenClinical trialsDrug developmentEndpointsTreatment

More Related Videos

Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

1.6K
Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells NPCs
10:47

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells NPCs

Published on: March 2, 2018

10.2K

Related Experiment Videos

Last Updated: Nov 1, 2025

Author Spotlight: Exploring Autism Spectrum Disorder Symptoms in Fruit Flies — Genetic Models and Behavioral Tests
08:30

Author Spotlight: Exploring Autism Spectrum Disorder Symptoms in Fruit Flies — Genetic Models and Behavioral Tests

Published on: September 6, 2024

2.1K
Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

1.6K
Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells NPCs
10:47

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells NPCs

Published on: March 2, 2018

10.2K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Targeted drug development for Autism Spectrum Disorder (ASD) has faced significant challenges and lack of progress.
  • The International Society for Computational Biology and Medicine (ISCTM) and the European College of Neuropsychopharmacology (ECNP) established the ASD Working Group in 2017 to address these issues.

Purpose of the Study:

  • Identify key barriers hindering therapeutic progress in ASD research.
  • Recommend research strategies to advance the development of novel ASD therapeutics.
  • Outline goals for next-generation biomedical interventions for ASD core features.

Main Methods:

  • Convened international experts from academia, regulatory bodies, and industry.
  • Conducted multiple meetings, teleconferences, and subgroup communications.
  • Gathered diverse perspectives on lessons learned, current challenges, and future research directions.

Main Results:

  • Identified major barriers including ASD heterogeneity, lack of validated biomarkers, need for improved clinical endpoints, target prioritization, and comorbidities.
  • Highlighted optimism for therapeutic advancements due to progress in basic ASD neuroscience.
  • Emphasized the potential of leveraging genetic data, intermediate phenotypes, digital phenotyping, big data analytics, refined endpoints, and early intervention.

Conclusions:

  • Substantial prospects exist for breakthrough treatments for ASD core symptoms.
  • Recommendations include prioritizing and expanding research funding for translational clinical ASD therapeutic research.
  • A concerted effort is needed to overcome existing challenges and accelerate therapeutic development in ASD.